Drug Trial Radar · NCT06372145
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
Last checked: Nov 20, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
2,500
Planned (sponsor's estimate)
Start
Apr 16, 2024
Primary completion
Apr 30, 2029
Study completion Apr 30, 2029
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Apr 17, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3 extension, global, multicenter study to assess the long-term safety and tolerability of tolebrutinib in adult participants (aged ≥18 years) with RMS, PPMS, or NRSPMS who were previously enrolled in the Phase 2b LTS (LTS16004) or 1 of the 4 Phase 3 tolebrutinib pivotal trials (GEMINI 1 \[EFC16033\], GEMINI 2 \[EFC16034\], HERCULES \[EFC16645\], or PERSEUS \[EFC16035\]). SUBSTUDY: ToleDYNAMIC substudy
Conditions
- Relapsing Multiple Sclerosis
- Secondary Progressive Multiple Sclerosis
- Progressive Relapsing Multiple Sclerosis
Interventions
TolebrutinibDrug
Pharmaceutical form:Tablet-Route of administration:oral
PlaceboDrug
Pharmaceutical form:Tablet-Route of administration:oral
TeriflunomideDrug
Pharmaceutical form:Tablet-Route of administration:oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs) and AEs leading to permanent study intervention discontinuationTime frame: From baseline until the End of study approximately 4 years per participant
- Number of Participants with Potentially clinically significant abnormalities (PCSAs)Time frame: From baseline until the End of study approximately 4 years per participant
Locations
352 sites in 47 countries. Site status is shown where the registry gives one.
The University of Alabama at Birmingham- Site Number : 8400013
Birmingham, Alabama
~North Central Neurology Associates, PC- Site Number : 8400009
Cullman, Alabama
Center for Neurology and Spine- Site Number : 8400089
Phoenix, Arizona
Collaborative Neuroscience Research- Site Number : 8400045
Los Alamitos, California
USC- Site Number : 8400143
Los Angeles, California
University of California San Diego Medical Center- Site Number : 8400101
San Diego, California
Regina Berkovich, MD, PhD- Site Number : 8400059
West Hollywood, California
University of Colorado- Site Number : 8400012
Denver, Colorado
Advanced Neurosciences Research- Site Number : 8400025
Fort Collins, Colorado
Georgetown University Medical Center- Site Number : 8400119
Washington D.C., District of Columbia
SFM Clinical Research, LLC- Site Number : 8400029
Boca Raton, Florida
University of Florida Health- Site Number : 8400159
Gainesville, Florida
Neurology Associates- Site Number : 8409902
Maitland, Florida
University of Miami- Site Number : 8400063
Miami, Florida
Aqualane Clinical Research- Site Number : 8400027
Naples, Florida
Axiom Clinical Research of Florida- Site Number : 8400001
Tampa, Florida
University of South Florida- Site Number : 8409905
Tampa, Florida
Velocity Clinical Research- Site Number : 8409903
Savannah, Georgia
Consultants In Neurology- Site Number : 8409906
Northbrook, Illinois
Springfield Clinic, LLP- Site Number : 8400071
Springfield, Illinois
Indiana University Health, Inc- Site Number : 8400039
Fort Wayne, Indiana
University of Kansas Medical Center- Site Number : 8400023
Kansas City, Kansas
University of Kentucky- Site Number : 8400106
Lexington, Kentucky
Norton Neurology MS Services- Site Number : 8400127
Louisville, Kentucky
The NeuroMedical Center- Site Number : 8400057
Baton Rouge, Louisiana
Ochsner Clinic Foundation- Site Number : 8400107
New Orleans, Louisiana
Tufts Medical Center- Site Number : 8400072
Boston, Massachusetts
University of Massachusetts- Site Number : 8400014
Worcester, Massachusetts
Wayne State University- Site Number : 8400046
Detroit, Michigan
Michigan Institute Neuro Disorders- Site Number : 8400058
Farmington Hills, Michigan
Memorial Healthcare Institute for Neuroscience- Site Number : 8400033
Owosso, Michigan
Minneapolis Clinic of Neurology- Site Number : 8400051
Golden Valley, Minnesota
Mayo Clinic- Site Number : 8400111
Rochester, Minnesota
Sharlin Health & Neurology- Site Number : 8400093
Ozark, Missouri
Missouri Baptist Medical Center- Site Number : 8400019
St Louis, Missouri
Lou Ruvo Center for Brain Health- Site Number : 8400117
Las Vegas, Nevada
University of New Mexico- Site Number : 8400032
Albuquerque, New Mexico
Mount Sinai Medical Center- Site Number : 8400038
New York, New York
NYU Langone South Shore Neurologic Associates- Site Number : 8400100
Patchogue, New York
Neurology Associates of Stony Brook- Site Number : 8400042
Stony Brook, New York
Showing 40 of 352 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.